Skip to main content
. 2021 Jan 5;11(1):e042587. doi: 10.1136/bmjopen-2020-042587

Figure 1.

Figure 1

Study flow diagram. Successful TAVR as defined in the ‘study population and methods’ section. *30 mg once daily if moderate or severe renal impairment (creatinine clearance 15 – 50 mL/min), low body weight ≤60kg or concomitant use of P-glycoprotein inhibitors (cyclosporin, dronedarone, erythromycin, ketoconazole). ASA, aspirin; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant.